Investor Alert

The Wall Street Journal Archives | Email alerts

March 19, 2019, 5:26 p.m. EDT

Bayer’s Roundup caused man’s cancer, jury finds; Monsanto liability trial up next

Another setback for Bayer, amid thousands of lawsuits targeting its herbicides

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Bayer AG (BAYN)

or Cancel Already have a watchlist? Log In

By Sara Randazzo and Ruth Bender

AFP/Getty Images
A customer shops for Roundup products at a store in San Rafael, Calif.

SAN FRANCISCO — A jury found that a man developed cancer from exposure to Roundup weedkiller he used in his yard, in the second case to go to trial over the alleged harms of the popular Bayer AG product.

The six-person jury in U.S. District Court in San Francisco now is set to begin hearing evidence to separately weigh whether Bayer’s /zigman2/quotes/210533053/delayed DE:BAYN -0.57%   Monsanto unit should be held liable, a decision that could bring substantial financial damages against the company.

The initial verdict marks another setback for Bayer, which has come under intense pressure since a jury in August reached a $289.2 million verdict in the first case over the weedkiller to go to trial. That verdict came down soon after Bayer finalized its acquisition of Monsanto Co.

Bayer faces lawsuits from about 11,200 farmers, home gardeners and landscapers claiming its glyphosate-based herbicides cause non-Hodgkin lymphoma and other cancers. Six more trials are due to start this year in federal and state courts.

An expanded version of this report appears on WSJ.com.

Also popular on WSJ.com:

How the National Enquirer got Jeff Bezos’ texts: It paid $200,000 to his lover’s brother.

The $1 million HOA blowup: It started with misplaces flower pots.

DE : Germany: Frankfurt
-0.34 -0.57%
Volume: 2,642
July 17, 2019 8:59p
P/E Ratio
Dividend Yield
Market Cap
Rev. per Employee

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.